Pharmaceutical Reform Alliance Releases New Report Detailing Big Pharma’s Role in Fueling America’s Affordability Crisis
Today, the Pharmaceutical Reform Alliance (PRA) released a report explaining how the pharmaceutical industry’s anti-competitive and anti-consumer business practices have led to higher healthcare costs, contributing to America’s affordability crisis. PRA is publishing the report, entitled "The State of U.S. Drug Pricing: Unaffordable," as healthcare affordability remains a top concern for American families, especially heading into this year’s elections.
New National Poll Finds Overwhelming Majorities of Voters Want “America First” Reforms of Big Pharma’s Business Practices, Want to Limit Direct-to-Consumer Pharmaceutical Advertising, & Support President Trump’s Executive Order on Drug Pricing
Today, the Pharmaceutical Reform Alliance (PRA) announced the results of a nationally representative poll of American voters, who overwhelmingly agree that it’s time to rein in Big Pharma, hold them accountable for soaring prescription drug costs, and implement commonsense reforms that make prescription drugs more affordable and more accessible for Americans.
